Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
Clinical trial NCT06895473 · RECRUITING
Trial details
- NCT number
- NCT06895473
- Sponsor
- OHSU Knight Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-04
- Primary completion
- 2027-04-30
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.